127 related articles for article (PubMed ID: 23948750)
21. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
22. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
23. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
24. Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma.
Bergsneider B; Bailey E; Ahmed Y; Gogineni N; Huntley D; Montano X
Biochem Biophys Rep; 2021 Sep; 27():101081. PubMed ID: 34307909
[TBL] [Abstract][Full Text] [Related]
25. High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.
Yndestad S; Austreid E; Knappskog S; Chrisanthar R; Lilleng PK; Lønning PE; Eikesdal HP
Breast Cancer Res Treat; 2017 May; 163(1):177-190. PubMed ID: 28213783
[TBL] [Abstract][Full Text] [Related]
26. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
27. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
28. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
[TBL] [Abstract][Full Text] [Related]
29. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer.
Roy-Luzarraga M; Abdel-Fatah T; Reynolds LE; Clear A; Taylor JG; Gribben JG; Chan S; Jones L; Hodivala-Dilke K
JAMA Netw Open; 2020 Oct; 3(10):e2019304. PubMed ID: 33107920
[TBL] [Abstract][Full Text] [Related]
30. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
31. TP53 signature diagnostic system using multiplex reverse transcription-polymerase chain reaction system enables prediction of prognosis of breast cancer patients.
Takahashi S; Fukui T; Nomizu T; Kakugawa Y; Fujishima F; Ishida T; Ohuchi N; Ishioka C
Breast Cancer; 2021 Nov; 28(6):1225-1234. PubMed ID: 34302605
[TBL] [Abstract][Full Text] [Related]
32. p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.
Fabi A; Mottolese M; Di Benedetto A; Sperati F; Ercolani C; Buglioni S; Nisticò C; Ferretti G; Vici P; Perracchio L; Malaguti P; Russillo M; Botti C; Pescarmona E; Cognetti F; Terrenato I
Clin Breast Cancer; 2020 Dec; 20(6):e761-e770. PubMed ID: 32580907
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
34. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.
King SI; Purdie CA; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Meek DW
Breast Cancer Res; 2012 Mar; 14(2):R40. PubMed ID: 22405092
[TBL] [Abstract][Full Text] [Related]
36. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I; Ameye L; Paesmans M; Larsimont D; Di Leo A; Dolci S; Piccart M; de Azambuja E; Loi S
Breast; 2014 Aug; 23(4):473-81. PubMed ID: 24768477
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.
Aas T; Geisler S; Eide GE; Haugen DF; Varhaug JE; Bassøe AM; Thorsen T; Berntsen H; Børresen-Dale AL; Akslen LA; Lønning PE
Eur J Cancer; 2003 Mar; 39(4):438-46. PubMed ID: 12751373
[TBL] [Abstract][Full Text] [Related]
38. Tumor hypoxia, p53, and prognosis in cervical cancers.
Haensgen G; Krause U; Becker A; Stadler P; Lautenschlaeger C; Wohlrab W; Rath FW; Molls M; Dunst J
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):865-72. PubMed ID: 11429213
[TBL] [Abstract][Full Text] [Related]
39. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Demosthenous C; Han JJ; Hu G; Stenson M; Gupta M
Oncotarget; 2015 Dec; 6(42):44703-13. PubMed ID: 26565811
[TBL] [Abstract][Full Text] [Related]
40. Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.
Guarneri V; Barbieri E; Piacentini F; Giovannelli S; Ficarra G; Frassoldati A; Maiorana A; D'Amico R; Conte P
Int J Biol Markers; 2010; 25(2):104-11. PubMed ID: 20544688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
